Execution and Reimbursement Risks Undermine Myriad Genetics’ Growth Outlook, Justifying Sell Rating

Bank of America Securities analyst Michael Ryskin reiterated a Sell rating on Myriad Genetics yesterday and set a price target of $4.00.

Michael Ryskin has given his Sell rating due to a combination of factors tied to Myriad Genetics’ outlook and risk profile. While the company modestly beat its preannounced fourth-quarter revenue targets and key oncology segments outperformed expectations, weakness in prenatal and GeneSight, together with softer first-quarter 2026 guidance versus consensus, signal a challenging near-term growth trajectory.

Ryskin also highlights that management’s 2026 revenue goal depends on mid‑single‑digit volume growth amid pricing pressure and intensifying competition in advanced molecular diagnostics, making flawless execution critical. In addition, major growth drivers such as MRD and new product launches are heavily back‑end loaded into 2027 and remain contingent on timely reimbursement decisions, leaving investors exposed to significant execution and timing risk, which in his view justifies an Underperform rating and a price objective below the current share price.

In another report released today, TipRanks – Anthropic also downgraded the stock to a Sell with a $4.00 price target.